Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0T7CM
|
||||
| Former ID |
DPR000117
|
||||
| Drug Name |
UCL-2000 and butabindide
|
||||
| Indication | Obesity [ICD9: 278; ICD10:E66] | Discontinued in Phase 1 | [1] | ||
| Company |
University College London
|
||||
| CAS Number |
CAS 185213-03-0
|
||||
| Target and Pathway | |||||
| Target(s) | Cholecystokinin receptor type A | Target Info | Agonist | [2] | |
| Tripeptidyl-peptidase II | Target Info | Inhibitor | [2] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Insulin secretion | |||||
| Pancreatic secretion | |||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (q) signalling eventsR-HSA-983168:Antigen processing: Ubiquitination & Proteasome degradation | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Clinical pipeline report, company report or official report of University College London. | ||||
| REF 2 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.